TRF2 as novel marker of tumor response to taxane-based therapy: from mechanistic insight to clinical implication.

ABSTRACT:

Background

Breast Cancer (BC) can be classified, due to its heterogeneity, into multiple subtypes that differ for prognosis and clinical management. Notably, triple negative breast cancer (TNBC) - the most aggressive BC form - is refractory to endocrine and most of the target therapies. In this view, taxane-based therapy still represents the elective strategy for the treatment of this tumor. However, due variability in patients' response, management of TNBC still represents an unmet medical need. Telomeric Binding Factor 2 (TRF2), a key regulator of telomere integrity that is over-expressed in several tumors, including TNBC, has been recently found to plays a role in regulating autophagy, a degradative process that is involved in drug detoxification. Based on these considerations,

SUBMITTER: Iachettini S 

PROVIDER: S-EPMC10924347 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature